MHRA Grants Romvimza Vimseltinib Approval for Tenosynovial Giant Cell Tumours

• The MHRA has approved vimseltinib (romvimza) for treating tenosynovial giant cell tumours in adults.
• This approval provides a new treatment option for patients who are unsuitable for surgery.
• Vimseltinib works by blocking the proteins that cause TGCTs to grow, slowing their progression and alleviating symptoms.
• The medication is subject to additional monitoring due to its potential impact on pregnancy and other side effects.

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to vimseltinib (romvimza), a treatment for tenosynovial giant cell tumours (TGCTs) in adults. This approval provides a new option for patients who are unsuitable for surgery, offering hope for those affected by this rare and often debilitating condition.

TGCT is a non-cancerous tumour that forms around joints and tendons, typically affecting young and middle-aged adults. The symptoms of TGCT can be severe, including pain, swelling, stiffness, and difficulty moving the affected joint. In some cases, surgery may not be possible or desirable, making vimseltinib's approval a significant development in the treatment of this condition.

The active ingredient in Romvimza, vimseltinib, works by blocking the proteins that cause TGCTs to grow, slowing their progression and alleviating symptoms. This medication is subject to additional monitoring due to its potential impact on pregnancy and other side effects.

The approval of vimseltinib was granted through the International Recognition Procedure (IRP) Route B, a process that allows for the recognition of marketing authorisations from other countries. The MHRA is responsible for regulating all medicines and medical devices in the UK, ensuring they meet rigorous safety and efficacy standards.

Deciphera Pharmaceuticals received the new marketing authorisation on 14 August 2026, marking a significant milestone in the development of this treatment. The Summary of Product Characteristics and Patient Information leaflets will be published on the MHRA Products website within 7 days of approval, providing healthcare professionals with essential information about vimseltinib's use and potential side effects.

The approval of vimseltinib is expected to have a significant impact on patients living with TGCTs who are unsuitable for surgery. This new treatment option offers hope for those affected by this rare condition, providing relief from symptoms and potentially improving quality of life.

Lawyers should note that the MHRA's approval of vimseltinib may require healthcare professionals to update their patient care protocols and ensure compliance with regulatory requirements. As with any medication, vimseltinib will be subject to ongoing monitoring by the MHRA to ensure its safety and effectiveness in treating TGCTs.

Lawyers should note that the MHRA has approved vimseltinib (romvimza) for treating tenosynovial giant cell tumours in adults, providing a new treatment option for patients who are unsuitable for surgery. This approval may impact compliance with regulatory requirements and patient care protocols.

Source: Original reporting via Medicines and Healthcare products Regulatory Agency